Snarr Brian S, Paridon Stephen M, Rychik Jack, Goldberg David J
1The Cardiac Center,The Children's Hospital of PhiladelphiaPhiladelphia,Pennsylvania,United States of America.
Cardiol Young. 2015 Dec;25(8):1489-92. doi: 10.1017/S1047951115002309.
The Fontan operation is the final step of palliation for patients with a functionally single ventricle. Since its introduction in the 1970s, the Fontan surgery has become part of a successful surgical strategy that has improved single ventricle mortality. In recent years, we have become more aware of the limitations and long-term consequences of the Fontan physiology. Pulmonary vascular resistance plays an important role in total cavopulmonary circulation, and has been identified as a potential therapeutic target to mitigate Fontan sequelae. In this review, we will discuss the results of different pulmonary vasodilator trials and the use of pulmonary vasodilators as a treatment strategy for Fontan patients.
Fontan手术是功能性单心室患者姑息治疗的最后一步。自20世纪70年代引入以来,Fontan手术已成为一种成功的手术策略的一部分,该策略降低了单心室患者的死亡率。近年来,我们越来越意识到Fontan生理学的局限性和长期后果。肺血管阻力在全腔静脉肺动脉循环中起重要作用,并已被确定为减轻Fontan后遗症的潜在治疗靶点。在本综述中,我们将讨论不同肺血管扩张剂试验的结果以及肺血管扩张剂作为Fontan患者治疗策略的应用。